---
title: "Morgan Stanley raises its revenue and adjusted profit forecasts for ALI HEALTH, target price raised to 6.5 yuan"
description: "JP Morgan raised its revenue and adjusted profit forecasts for ALI HEALTH, increasing the target price from 5 yuan to 6.5 yuan. The bank believes that ALI HEALTH's stock price has risen approximately "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257640578.md"
published_at: "2025-09-17T02:30:20.000Z"
---

# Morgan Stanley raises its revenue and adjusted profit forecasts for ALI HEALTH, target price raised to 6.5 yuan

> JP Morgan raised its revenue and adjusted profit forecasts for ALI HEALTH, increasing the target price from 5 yuan to 6.5 yuan. The bank believes that ALI HEALTH's stock price has risen approximately 27% since the announcement of its fiscal year 2025 results in May, mainly benefiting from investors' positive response to the updated online retail policy for prescription drugs. It is expected that the synergy with Taobao's fast e-commerce will drive user and order growth, maintaining a "Neutral" rating

JP Morgan published a report stating that Alibaba Health (00241.HK) stock price has increased by approximately 27% since the announcement of its fiscal year 2025 results in May, surpassing its peers by 8 percentage points. The bank believes this is mainly due to investors' positive reaction to the recent updates in online retail sales policies for prescription drugs. Given that this is essentially a guideline with no substantial differences from existing policies, the impact is considered to be more on the emotional level. The bank believes that the synergy with Taobao's fast e-commerce will remain a key focus for the first half of the current fiscal year ending in September, specifically including growth in users and order volume, potential investment scale and forms, and user churn after subsidy normalization.

The bank has raised its revenue forecasts for Alibaba Health for the current and next fiscal years by 4% each, reflecting the synergy in user traffic and overall gross merchandise volume with Taobao's fast e-commerce, and has also raised its adjusted earnings per share forecasts for the current and next fiscal years by 3% and 4% respectively, reflecting the marketing savings brought by Taobao's high subsidies for fast e-commerce, partially offset by investments caused by business collaboration. The target price has been raised from HKD 5 to HKD 6.5, equivalent to a projected price-to-sales ratio of 2.5 times for the current fiscal year, maintaining a "Neutral" rating

### Related Stocks

- [00241.HK - ALI HEALTH](https://longbridge.com/en/quote/00241.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alibaba founder Jack Ma says children should be taught how to use AI, not whether to use it | Jack Ma emphasized the importance of teaching children how to effectively use AI rather than debating its use. Speaking  | [Link](https://longbridge.com/en/news/273939770.md) |
| Alibaba Health Information Technology Ltd. held special general meeting | Alibaba Health Information Technology Ltd. held a special general meeting on December 30, 2025, where shareholders appro | [Link](https://longbridge.com/en/news/271105388.md) |
| Mawana Sugars Shareholders Clear Amalgamation With Mawana Foods | Mawana Sugars Limited's shareholders have approved the amalgamation of Mawana Foods Private Limited into Mawana Sugars,  | [Link](https://longbridge.com/en/news/276516853.md) |
| Tesla Moves Beyond Vehicles in India with AI Hiring Push | Tesla is expanding its operations in India by hiring for two key AI-focused positions: an AI Hardware Engineer and a Sit | [Link](https://longbridge.com/en/news/276517340.md) |
| Pezeshkian says Iran will not bow to pressure amid US nuclear talks | Feb 21 (Reuters) - Iranian President Masoud Pezeshkian said on Saturday that his country would not bow its head to press | [Link](https://longbridge.com/en/news/276515418.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.